Compare Prologis Inc (PLD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prologis Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Prologis Inc trades at $135.32 (market cap $131.60B), while Vertex Pharmaceuticals Incorporated trades at $521.58 (market cap $134.06B). The key difference: Prologis Inc and Vertex Pharmaceuticals Incorporated are close in size by market cap, and Prologis Inc pays a 3.09% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| PLD | VRTX | |
|---|---|---|
Market Cap | $131.60B | $134.06B |
Sector | Real Estate | Health |
52-Week High | $149.96 | $557.96 |
52-Week Low | $110.98 | $376.62 |
Enterprise Value | $166.34B | $128.18B |
Dividend Yield | 3.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prologis (PLD) trades at $138.49, up 0.84% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue grew to $8.79B in 2025, and the company maintains high profit margins. Analyst consensus is bullish with a $160.13 price target, though technical indicators show near-term pressure with support at $137.
The outlook for PLD is positive due to consistent earnings beats and robust institutional interest, but risks include rising debt levels and market volatility. The stock offers growth potential from its real estate portfolio, yet investors should monitor debt-to-asset trends and economic conditions affecting REIT valuations.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
